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medication prescribed to treat it. Pain Management Index 
(PMI) is calculated by subtracting the patient-rated pain 
intensity score from the analgesic score. A negative PMI score 




58 patients were available for analysis, 51 males and 7 
females with median age of 54 years. 
Of these, 72.4% patients were stage III disease and 27.6% 
were stage IV. Majority were oral cavity primary (36.2%) 
followed by oropharynx (24.1%), larynx (22.2%) and 
hypopharynx (8.6%) 72% patients reported pain for 0-6 
months prior to study entry. On average, pain intensity 
measure before start of CCRT was 2.14(mild), 8.60( severe) 
at 3 weeks of RT, 6.01(moderate) at the end and 1.36(mild) 
at 3 months of follow-up.  
Mean score for Worst Pain intensity was 8.7 at 3 weeks of 
treatment.Patients who received opioids (mild/strong) before 
start of RT, at 3 weeks of treatment and at the end were 
6.91%, 20.69% and 10.34% respectively. Most common 
neuropathic pain descriptors chosen were- Aching (60.34%) 
and Burning (36.21%); nociceptive words chosen were- 
Throbbing (84.48%), Shooting (37.93%) and Tender (34.48%) 
and Affective descriptors were Tiring (70.68%) and Nagging 
(55.17%).  
> 50% pain relief with the analgesics prescribed was attained 
by 70.68% patients before start of therapy, 65.51% and 
82.76% at 3 weeks and end of therapy respectively.Based on 
PMI, during radiation 44.83% (26/58) and at the end of 
therapy 34.48% (20/58) patients received undertreatment for 
their level of pain intensity. 
Conclusions: Inadequate pain management appears to be a 
persistent problem for patients undergoing radiotherapy. 
Clinical management of both nociceptive as well as 
neuropathic components and more appropriate and judicious 
use of strong opioids can contribute to improved pain relief. 
Future educational efforts should therefore target radiation 
oncologists as an important resource for treatment of cancer 
pain. 
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Purpose/Objective: Lung metastasectomy and Stereotactic 
Ablative Radiotherapy (SABR) are proposed to selected stage 
IV oligo-metastatic colo-rectal cancer (CRC) patients in 
absence of clear evidence of superiority of any of the two 
approaches. Aim of the present retrospective cohort study 
was to perform an explorative comparison of the two 
treatments (SABR vs. surgery) on overall survival.  
Materials and Methods: All patients who consecutively were 
referred to the Thoracic Surgery Unit and underwent surgery 
(n=180) or to the Radiation Oncology Unit an underwent SABR 
(n=28) as first local therapy for lung metastases between 
2005 and 2012 were considered for analysis. SABR was 
delivered with a single fraction of 26 Gy prescribed at the 
80% isodose. Surgery consisted in nonanatomic wedge 
resections. Overall survival functions according to treatment 
were calculated using Kaplan-Meier method and compared 
using Log-rank test. Crude and adjusted hazard ratios 
(controlling for age, gender, comorbidities, CEA levels and 
disease-free interval) were estimated by Cox models. A 
sensitivity analysis was also performed by using the 
propensity score (inverse probability treatment weighting 
method). 
Results: Patients receiving SABR were older and were treated 
more recently, had less lung metastases, while comorbidities 
and size of the treated lesions were similar in the two 
groups. Median follow-up were 36 months for the surgical 
cohort and 30 months for the SABR cohort. Overall survival at 
1 and 2 years were 0.89 and 0.77 for SABR group and 0.94 
and 0.80 for surgery group (log-rank test p-value=0.24), 
thereafter the survival seems to be lower for the SABR group 
(fig1). After adjustement, the HR of SABR vs surgery was 
1.51(95%CI:0.75-3.04; p=0.24). These results were confirmed 
in the sensitivity analysis. 
Conclusions: Results of the present study shows that overall 
survival probability after SABR is similar to surgery, at least 
for the first two years from treatment. The survival 
projection is limited afterwards as the follow-up of the SABR 
cohort is shorter. These results suggest that SABR should be 
included as a local treatment option in a randomized trial. 
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Purpose/Objective: A proportion of patients diagnosed with 
head and neck cancer (HNC) cannot be treated with curative 
intent. Although incurable, these patients may benefit from 
high-dose radiotherapy (RT). Since symptoms are often 
directly related to the size of the primary tumour and/or 
involved lymph nodes, treatment should result in a 
substantial reduction of tumour volume. By limiting the 
number of fractions and including only macroscopically 
involved areas treatment burden can remain limited. This 
retrospective study evaluates efficacy and tolerability of 
high-dose hypofractionated radiotherapy in patients 
diagnosed with head and neck cancer (HNC).  
Materials and Methods: All patients with HNC who were 
palliatively treated between September 2003 and September 
2013 with 12 x 4 Gy radiotherapy, 3-4 x per week, as a single 
modality were included. EQD2(α/β10) was 66-70 Gy, depending 
on overall treatment time. 2D/3D-techniques or IMRT were 
used. Primary endpoints were palliative effect and overall 
survival. Palliative effect was classified as positive if positive 
subjective outcomes, like pain relief, a decrease in dysphagia 
or improvement of other complaints previously expressed by 
the patient, were documented. Palliative effect was 
classified as absent if no such improvements were 
documented and/or if patients experienced persistent 
toxicity of RT.  
Secondary endpoints were tumour response, loco-regional 
progression and toxicity. Primary tumour and regional 
metastases responses were noted as complete response (CR), 
partial response (PR), stable disease (SD) or progressive 
disease (PD) according to the RECIST response grading 
system. All endpoints were evaluated from the start of 
radiotherapy. 
Results: In total, 81 patients were included. IMRT was 
applied in 33 patients (41%) and 2D-techniques were applied 
in 48 patients (59%). Palliative effect was observed in 56% of 
patients, with a median duration of 4.6 months. Palliative 
effect occurred after a median follow-up of 2.2 months and 
was correlated with tumour response (p = 0.006). Median 
overall survival (OS) was 7.2 months. Histological type, 
tumour response, tumour stage, primary tumour site and 
palliative effect were correlated with survival (p < 0.05). 
Overall response rate was 88% and complete response rate 
was 32%, 1- and 2-year OS were 26% and 9% respectively. 
Moist desquamation was observed in 21% and confluent 
mucositis in 70% of patients, mucositis was observed more 
often in patients treated with 2D/3D techniques compared to 
IMRT (p = 0.04). These reactions lasted for a median duration 
of 2 weeks. 
Conclusions: High-dose hypofractionation radiotherapy (12x4 
Gy) resulted in a clinically meaningful palliation of symptoms 
and limited toxicity in 56% of patients, lasting for almost 5 
months. Toxicity appeared to be acceptable and was 
significantly lower when IMRT was used to reduce the 
irradiated normal tissue volume. We therefore recommend 
hypofractionated high-dose IMRT for head and neck cancer 
patients who have a life expectancy of at least 6 months. 
